[ET Net News Agency, 2 September 2021] CStone Pharmaceuticals (02616) said the National
Medical Products Administration (NMPA) of China has accepted the new drug application
(NDA) for sugemalimab as a consolidation therapy in patients with unresectable stage III
NSCLC non-small cell lung cancer (NSCLC) without disease progression after concurrent or
sequential chemoradiotherapy. It is the eighth NDA/supplemental NDA submitted by CStone.
Sugemalimab is an investigational anti-PD-L1 monoclonal antibody discovered by CStone.
Authorized by the U.S.-based Ligand Corporation, sugemalimab is developed by the OmniRat
transgenic animal platform, which can generate fully human antibodies in one stop. (RC)